David Parfitt
Senior Scientist ProQR Therapeutics
David Parfitt, Ph.D., is a Senior Scientist at ProQR Therapeutics, where he has worked since November 2021. Previously, he served as a Researcher at Leiden University Medical Center (2019–2021) and as a Research Associate at the UCL Institute of Ophthalmology (2011–2019), focusing on inherited retinal diseases. He earned his Ph.D. in Cell Biology from Queen Mary University of London and a B.Sc. in Biology from the University of York. Dr. Parfitt brings deep molecular expertise to the development of transformative RNA therapies targeting rare genetic disorders.
Seminars
Thursday 11th December 2025
From Chemical Design Optimization to Clinical Application: Advancing ADAR RNA Editing in Liver and CNS
2:30 pm
- ADAR-mediated RNA editing as a versatile therapeutic approach to precisely correct disease-causing RNA mutations, modulate protein expression levels, or alter protein function to prevent or treat disease
- Optimization of editing oligonucleotides (EONs) through chemical modifications to enhance editing efficiency, specificity, and cellular uptake
- Translation of optimized EON strategies into therapeutically relevant applications addressing high unmet medical needs in the liver and CNS.
